Literature DB >> 35138549

Understanding and co-managing medication treatment options for opioid use disorder.

Abigail Kay1, Rachel Shmuts2, Melanie Beck3.   

Abstract

The number of patients with opioid use disorder (OUD) has increased dramatically. Substance use disorders in general are thought to occur in one in five patients in primary care. However, despite this prevalence, there is a dearth of training in undergraduate and continuing medical education to manage OUDs, and internal medicine doctors need to have an understanding of the basic physiology and treatment options for this illness. Expanding knowledge of OUD treatments will allow internists to use their skills and strong patient-doctor relationships to ensure the trust of their patients with OUD, leading to better outcomes and increased chances of recovery. It will also allow clinicians to appropriately refer their patients for lifesaving specialized care and help them prevent dangerous medical complications often seen as a result of addiction. There are three FDA-approved medications to treat OUD disorder, known collectively as medication-assisted treatment (MAT). In this paper, the three medications-methadone, naltrexone, and buprenorphine-are presented, compared, contrasted, and clinically reviewed.
© 2022. The Author(s), under exclusive licence to Società Italiana di Medicina Interna (SIMI).

Entities:  

Keywords:  Buprenorphine; Medication-assisted treatment; Methadone; Naltrexone; Opioid use disorder

Mesh:

Substances:

Year:  2022        PMID: 35138549     DOI: 10.1007/s11739-022-02936-8

Source DB:  PubMed          Journal:  Intern Emerg Med        ISSN: 1828-0447            Impact factor:   5.472


  6 in total

1.  Treatment of pain in patients taking buprenorphine for opioid addiction #221.

Authors:  Julie W Childers; Robert M Arnold
Journal:  J Palliat Med       Date:  2012-05       Impact factor: 2.947

Review 2.  Methadone maintenance in the treatment of opioid dependence. A current perspective.

Authors:  J E Zweben; J T Payte
Journal:  West J Med       Date:  1990-05

3.  Concurrent Initiation of Hepatitis C and Opioid Use Disorder Treatment in People Who Inject Drugs.

Authors:  Elana S Rosenthal; Rachel Silk; Poonam Mathur; Chloe Gross; Rahwa Eyasu; Laura Nussdorf; Kristi Hill; Christopher Brokus; Aaron D'Amore; Nadeera Sidique; Phyllis Bijole; Miriam Jones; Randy Kier; Dana McCullough; David Sternberg; Kristen Stafford; Junfeng Sun; Henry Masur; Shyamasundaran Kottilil; Sarah Kattakuzhy
Journal:  Clin Infect Dis       Date:  2020-10-23       Impact factor: 9.079

Review 4.  Neurocircuitry of addiction.

Authors:  George F Koob; Nora D Volkow
Journal:  Neuropsychopharmacology       Date:  2010-01       Impact factor: 7.853

Review 5.  Prescription opioid abuse: a literature review of the clinical and economic burden in the United States.

Authors:  Roxanne Meyer; Anisha M Patel; Stacy K Rattana; Tiffany P Quock; Samir H Mody
Journal:  Popul Health Manag       Date:  2014-12       Impact factor: 2.459

Review 6.  Novel Investigations of Flavonoids as Chemopreventive Agents for Hepatocellular Carcinoma.

Authors:  Chen-Yi Liao; Ching-Chang Lee; Chi-chang Tsai; Chao-Wen Hsueh; Chih-Chiang Wang; I-Hung Chen; Ming-Kai Tsai; Mei-Yu Liu; An-Tie Hsieh; Kuan-Jen Su; Hau-Ming Wu; Shih-Chung Huang; Yi-Chen Wang; Chien-Yao Wang; Shu-Fang Huang; Yen-Cheng Yeh; Ren-Jy Ben; Shang-Tao Chien; Chin-Wen Hsu; Wu-Hsien Kuo
Journal:  Biomed Res Int       Date:  2015-12-16       Impact factor: 3.411

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.